Investing.com - Co-Diagnostics (NASDAQ: CODX) reported second quarter EPS of $-0.310, $0.07 worse than the analyst estimate of $-0.240. Revenue for the quarter came in at $200K versus the consensus estimate of $500K.
Co-Diagnostics's stock price closed at $1.210. It is down -9.020% in the last 3 months and down -81.270% in the last 12 months.
Co-Diagnostics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Co-Diagnostics's stock price’s past reactions to earnings here.
According to InvestingPro, Co-Diagnostics's Financial Health score is "fair performance".
Check out Co-Diagnostics's recent earnings performance, and Co-Diagnostics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar